NEW YORK (360Dx) – Accelerate Diagnostics reported after the close of the market on Wednesday that its preliminary first quarter revenues increased 325 percent year over year to $530,000 from $163,000 in the prior-year quarter.

The figure would miss the average analysts' estimate of $742,000 in revenues, however.

The increase was driven by capital sales of the Accelerate Pheno system in the US and sales of the Accelerate PhenoTest BC kit across the US and Europe, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.